CORONAVIRUS INFECTION AND DYSLIPIDEMIA — IS THERE A CONNECTION?

Abstract

Dyslipidemia is one of the most common concomitant conditions in patients infected with the SARS—CoV-2 coronavirus. Based on the analysis of current literature, the review evaluates the possible effect of dyslipidemia on the course of the disease and prognosis in patients with coronavirus infection (COVID
19), as well as the effect of virus infection on the lipid profile in patients with dyslipidemia. The inflammatory process in COVID-19 leads to an increase in the
concentration of high-density lipoproteins (HDL), modulation of apolipoproteins, an increase in serum concentration of amyloid protein A and a decrease in the content of apolipoproteins A-I, M and E, which has a negative effect on the antioxidant, anti inflammatory and immunomodulatory role of HDL. The use of statins in patients with COVID-19 may help reduce the risk of lipid metabolism disorders. By reducing the synthesis of endogenous cholesterol, statins reduce its amount in lipid rafts, which can limit the penetration of SARS-CoV-2 into host cells. In addition, statins, by reducing the overexpression of proinflammatory cytokines, reduce the intensity of the "cytokine storm" accompanying COVID-19